Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy
Renal cell carcinoma (RCC) is a heterogeneous disease comprising a variety of histological subtypes. Approximately 70–80% of RCC cases are clear cell carcinoma (ccRCC), while the remaining subtypes constitute non-clear cell carcinoma (nccRCC). The medical treatment of RCC has greatly changed in rece...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/11/2840 |
| _version_ | 1797469017908183040 |
|---|---|
| author | Kazutoshi Yamana Riuko Ohashi Yoshihiko Tomita |
| author_facet | Kazutoshi Yamana Riuko Ohashi Yoshihiko Tomita |
| author_sort | Kazutoshi Yamana |
| collection | DOAJ |
| description | Renal cell carcinoma (RCC) is a heterogeneous disease comprising a variety of histological subtypes. Approximately 70–80% of RCC cases are clear cell carcinoma (ccRCC), while the remaining subtypes constitute non-clear cell carcinoma (nccRCC). The medical treatment of RCC has greatly changed in recent years through advances in molecularly targeted therapies and immunotherapies. Most of the novel systemic therapies currently available have been approved based on ccRCC clinical trial data. nccRCC can be subdivided into more than 40 histological subtypes that have distinct clinical, histomorphological, immunohistochemical, and molecular features. These entities are listed as emerging in the 2022 World Health Organization classification. The diagnosis of nccRCC and treatments based on cancer histology and biology remain challenging due to the disease’s rarity. We reviewed clinical trials focused on recent discoveries regarding clinicopathological features. |
| first_indexed | 2024-03-09T19:15:31Z |
| format | Article |
| id | doaj.art-c73e2949b35c40888306de5364160001 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T19:15:31Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-c73e2949b35c40888306de53641600012023-11-24T03:51:34ZengMDPI AGBiomedicines2227-90592022-11-011011284010.3390/biomedicines10112840Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment StrategyKazutoshi Yamana0Riuko Ohashi1Yoshihiko Tomita2Department of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata 951-8510, JapanDivision of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata 951-8510, JapanDepartment of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata 951-8510, JapanRenal cell carcinoma (RCC) is a heterogeneous disease comprising a variety of histological subtypes. Approximately 70–80% of RCC cases are clear cell carcinoma (ccRCC), while the remaining subtypes constitute non-clear cell carcinoma (nccRCC). The medical treatment of RCC has greatly changed in recent years through advances in molecularly targeted therapies and immunotherapies. Most of the novel systemic therapies currently available have been approved based on ccRCC clinical trial data. nccRCC can be subdivided into more than 40 histological subtypes that have distinct clinical, histomorphological, immunohistochemical, and molecular features. These entities are listed as emerging in the 2022 World Health Organization classification. The diagnosis of nccRCC and treatments based on cancer histology and biology remain challenging due to the disease’s rarity. We reviewed clinical trials focused on recent discoveries regarding clinicopathological features.https://www.mdpi.com/2227-9059/10/11/2840renal cell carcinomadrug therapyhistological subtypesimmunotherapybiology-driven treatment strategy |
| spellingShingle | Kazutoshi Yamana Riuko Ohashi Yoshihiko Tomita Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy Biomedicines renal cell carcinoma drug therapy histological subtypes immunotherapy biology-driven treatment strategy |
| title | Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy |
| title_full | Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy |
| title_fullStr | Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy |
| title_full_unstemmed | Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy |
| title_short | Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy |
| title_sort | contemporary drug therapy for renal cell carcinoma evidence accumulation and histological implications in treatment strategy |
| topic | renal cell carcinoma drug therapy histological subtypes immunotherapy biology-driven treatment strategy |
| url | https://www.mdpi.com/2227-9059/10/11/2840 |
| work_keys_str_mv | AT kazutoshiyamana contemporarydrugtherapyforrenalcellcarcinomaevidenceaccumulationandhistologicalimplicationsintreatmentstrategy AT riukoohashi contemporarydrugtherapyforrenalcellcarcinomaevidenceaccumulationandhistologicalimplicationsintreatmentstrategy AT yoshihikotomita contemporarydrugtherapyforrenalcellcarcinomaevidenceaccumulationandhistologicalimplicationsintreatmentstrategy |